Advertisement

Der Nervenarzt

, Volume 86, Issue 11, pp 1420–1423 | Cite as

Sollen bei Prodromalstadien der Schizophrenie Antipsychotika zur Psychoseprävention eingesetzt werden? Pro

  • M. LambertEmail author
  • C. Correll
Pro und Kontra
Innerhalb einer Pro- und Kontra-Debatte versucht der vorliegende Artikel die Frage zu beantworten, ob und unter welchen Umständen Antipsychotika, alleine oder in Kombination mit psychosozialen Interventionen, zur Psychoseprävention im Prodromalstadium psychotischer Störungen eingesetzt werden sollten. Diesbezüglich bestehen zwei wesentliche Fragen:
  • Welche Gründe bzw. Evidenzen rechtfertigen den Einsatz von Antipsychotika?

  • Was sind die Risiken einer Antipsychotikabehandlung vs. eine Nichtbehandlung?

Gründe bzw. Evidenzen für Antipsychotika zur Psychoseprävention

Das wichtigste Behandlungsziel im Prodrom ist die Verhinderung des Übergangs in eine psychotische Erkrankung. Innerhalb von 3 Jahren haben durchschnittlich etwa ein Drittel der Patienten mit einem Hochrisikoprodrom einen Übergang in ein psychotisches Vollbild (1. Jahr 22 %, 2. Jahr 29 %, 3. Jahr 36 % [1]). Entsprechend ist im Prodrom das Risiko, eine Psychose innerhalb eines Jahres zu entwickeln, im Vergleich zur...

Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Lambert und C. Correll geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Fusar-Poli P, Bonoldi I, Yung AR et al (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69:220–229CrossRefPubMedGoogle Scholar
  2. 2.
    Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251CrossRefPubMedGoogle Scholar
  3. 3.
    Cannon TD, Cadenhead K, Cornblatt B et al (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65:28–37PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Marshall M, Rathbone J (2011) Early intervention for psychosis. Cochrane Database Syst Rev 15:CD004718Google Scholar
  5. 5.
    Stafford MR, Jackson H, Mayo-Wilson E et al (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:185CrossRefGoogle Scholar
  6. 6.
    Gaag M van der, Smit F, Bechdolf A et al (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149:56–62CrossRefPubMedGoogle Scholar
  7. 7.
    Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388–404CrossRefPubMedGoogle Scholar
  8. 8.
    McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928CrossRefPubMedGoogle Scholar
  9. 9.
    Phillips LJ, McGorry PD, Yuen HP et al (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96:25–33CrossRefPubMedGoogle Scholar
  10. 10.
    McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799CrossRefPubMedGoogle Scholar
  11. 11.
    Woods SW, Breier A, Zipursky RB et al (2003) Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 54:453–464CrossRefPubMedGoogle Scholar
  12. 12.
    McGorry PD, Nelson B, Phillips LJ et al (2013) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 74:349–356CrossRefPubMedGoogle Scholar
  13. 13.
    Yung AR, Phillips LJ, Nelson B et al (2011) Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry 72:430–440CrossRefPubMedGoogle Scholar
  14. 14.
    Phillips LJ, Nelson B, Yuen HP et al (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 43:818–829CrossRefPubMedGoogle Scholar
  15. 15.
    Ruhrmann S, Bechdolf A, Kühn KU (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:88–95CrossRefGoogle Scholar
  16. 16.
    Woods SW, Tully EM, Walsh BC et al (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:96–101CrossRefGoogle Scholar
  17. 17.
    Kobayashi H, Morita K, Takeshi K et al (2009) Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol 29:421–425CrossRefPubMedGoogle Scholar
  18. 18.
    Walker EF, Cornblatt BA, Addington J et al (2009) The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res 115:50–57PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Liu CC, Chien YL, Hsieh MH et al (2013) Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. J Clin Psychopharmacol 33:18–23CrossRefPubMedGoogle Scholar
  20. 20.
    Washida K, Takeda T, Habara T et al (2013) Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. Neuropsychiatr Dis Treat 9:861–868PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Tsujino N, Nemoto T, Morita K et al (2013) Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial. Clin Psychopharmacol Neurosci 211:132–136CrossRefGoogle Scholar
  22. 22.
    Simon AE, Velthorst E, Nieman DH et al (2011) Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 132:8–17CrossRefPubMedGoogle Scholar
  23. 23.
    Howes OD, Kambeitz J, Kim E et al (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776–786PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Howes OD, Bose SK, Turkheimer F et al (2011) Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168:1311–1317PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Egerton A, Chaddock CA, Winton-Brown TT et al (2013) Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry 74:106–112CrossRefPubMedGoogle Scholar
  26. 26.
    Abi-Dargham A, Giessen E van de, Slifstein M et al (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry 65:1091–1093CrossRefPubMedGoogle Scholar
  27. 27.
    Howes O, Bose S, Turkheimer F et al (2011) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 16:885–886CrossRefPubMedGoogle Scholar
  28. 28.
    Delespaul PH, de consensusgroep EPA (2013) Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands. Tijdschr Psychiatr 55:427–438PubMedGoogle Scholar
  29. 29.
    Correll CU (2007) Acute and long-term adverse effects of antipsychotics. CNS Spectr 12(Suppl 21):10–14PubMedGoogle Scholar
  30. 30.
    Aderhold V, Weinmann S, Hägele C et al (2013) Can long-term treatment with antipsychotic drugs lead to structural brain damage? Nervenarzt 84:1117–1119CrossRefPubMedGoogle Scholar
  31. 31.
    Aderhold V, Weinmann S, Hägele C et al (2015) Frontal brain volume reduction due to antipsychotic drugs? Nervenarzt 86:302–323CrossRefPubMedGoogle Scholar
  32. 32.
    Fusar-Poli P, Smieskova R, Kempton MJ et al (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37:1680–1691PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Szöke A, Trandafir A, Dupont ME et al (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 192:248–257CrossRefPubMedGoogle Scholar
  34. 34.
    Nielsen RE, Levander S, Kjaersdam Telleus G et al (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia – a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131:185–196CrossRefPubMedGoogle Scholar
  35. 35.
    Lesh TA, Tanase C, Geib BR et al (2015) A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry 72:226–234CrossRefPubMedGoogle Scholar
  36. 36.
    Andreasen NC, Liu D, Ziebell S et al (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 170:609–615CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Arbeitsbereich Psychosen, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Zentrum für Psychosoziale MedizinUniversitätsklinikum Hamburg-Eppendorf (UKE)HamburgDeutschland
  2. 2.Recognition and Prevention ProgramThe Zucker Hillside HospitalGlen OaksUSA

Personalised recommendations